Antibiotic resistance is a hot topic in long-term care, and a new study indicates non-antibiotic therapeutic drugs are already available. Most provocatively, an antipsychotic may be used to treat Clostridium difficile.
Coping with the complicated management of infectious diseases is among the many challenges facing long-term care facilities today. Residents with multiple comorbidities often are prescribed broad-spectrum antibiotics and it seems as though methicillin-resistant Staphylococcus aureus (MRSA) and other (increasingly) drug-resistant bugs are everywhere. Outbreaks are common, ranging from norovirus and influenza to Clostridium difficile and scabies.
PDI's new Sani-Cloth® Pail and Refill format for Sani-Cloth® Bleach and Sani-Cloth® AF3 Germicidal Disposable Wipes is designed to meet needs of environmental services, the company announced.
A potential Clostridium difficile vaccine performed well in initial tests and now has moved into a large Phase III trial, researchers announced today. The news from developer Sanofi Pasteur raises hopes that the antibiotic-resistant infection can be prevented in long-term care facilities and other settings where it has become a deadly scourge.
Fecal transplants to cure Clostridium difficile could become more common, following a trial that successfully used frozen stool specimens, according to researchers at Massachusetts General Hospital.
Hospitals and post-acute facilities in Washington state have cut their rate of Clostridium difficile infections in half since 2012 by partnering with each other in a robust infection control program, according to local news reports.
Performing hand hygiene prior to putting on gloves may not be a necessary practice, suggests recently published research in the American Journal of Infection Control.
Healthcare workers frequently have Clostridium difficile spores on their hands after providing routine care for an infected person, and nursing assistants have by far the highest incidence of contamination, according to recently published research from France.
Long-term care facilities and other healthcare providers are not required to dispose of contaminated linen as "regulated waste," the Occupational Safety and Health Administration clarified in a recent letter.
New research challenges assumptions about how Clostridium difficile is transmitted.
Pills created from fecal matter are the latest breakthrough in treating Clostridium difficile, according to a doctor in Canada who says he has cured about 30 people this way.
High and low dosages of a popular antibiotic are equally good at combating Clostridium difficile infections, according to a new study.
Sanofi Pasteur's vaccine division has started a Phase III clinical trial to evaluate the safety and efficacy of a vaccine for Clostridium difficile.
A new study contradicts widely held assumptions about how Clostridium difficile infection occurs, which may lead long-term care providers to step up control measures.
People who take proton-pump inhibitor medications are at increased risk for developing a Clostridium difficile infection, according to a recently published study that supports previous findings.
Antibiotic resistance leads to 23,000 deaths a year, providers must implement best practices: CDC 'landmark' reportSeptember 17, 2013
Nursing homes are on the front lines in the increasingly urgent battle against antibiotic-resistant infections, according to a comprehensive new report that ranks the most dangerous antibiotic-resistant microorganisms. The report identifies four core actions to fight the spread of antibiotic resistance.
High and low dosages of a popular antibiotic offer little difference in the outcomes of Clostridium difficile infections, according to a new study.
The bacterial infection Clostridium difficile is most effectively diagnosed through a method called cytotoxin assay, a new study has found.
Probiotics are not effective in preventing diarrhea associated with Clostridium difficile, according to a large study that calls into question previous findings.
Back in June, I declared medication to be the long-term care topic of the summer. But this week, a different topic has stolen the spotlight: Clostridium difficile.
Antibiotics often aren't enough to combat Clostridium difficile. But when combined with probiotics, or "good" bacteria, the results are striking. The treatment combo lessens the likelihood of C. diff symptoms by 64%, according to a recent study.
Individuals with treatment-resistant Clostridium difficile can undergo fecal transplants after giving informed consent, the Food and Drug Administration recently announced. This is a victory for providers, who pushed back after the FDA recently announced it would tighten regulations around the transplants.
Clostridium difficile poses a serious public health threat and potential treatments should be fast-tracked, the Food and Drug Administration stated in a newly proposed regulation.
Long-term care facilities dealing with an outbreak of Clostridium difficile have a good chance of reducing symptoms of the infection by administering probiotics, according to a recently released comprehensive review of randomized trials.
Depressed or lonely people are at increased risk of Clostridium difficile infection, according to research in BMC Medicine.
New strains of drug-resistant pathogens are targets of more scrutiny among infection control professionals employed in long-term care environments.
The Food and Drug Administration is moving to tighten regulations around fecal transplants, which research has shown to be an effective treatment for Clostridium difficile infection.
People who are depressed or lonely are at increased risk of Clostridium difficile infection, according to recently published research.
Long-term care providers might want to pay special attention to residents with certain recently identified risk factors for Clostridium difficile. These factors are chronic dialysis, recent hospitalization and use of corticosteroids such as prednisone.
Pfizer must pay $142 million for the marketing and prescribing of epilepsy drug Neurontin for unapproved uses, a federal appeals court has ruled. The justices refused to overturn a jury's previous verdict. The jury determined Pfizer marketed Neurontin for bipolar disorder, migraines and neuropathic pain. The Food and Drug Administration had not approved the medicine for any of those uses.